Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PHILLIP MADONIA

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1871685917
CMS profile
387975
Location
MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$356.73

29 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $356.73 29

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PHILLIP MADONIA

NPI 1871685917 · CMS profile ID 387975

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

MOBILE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871685917?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PHILLIP MADONIA, NPI 1871685917, CMS profile ID 387975. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871685917?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). PHILLIP MADONIA, NPI 1871685917, CMS profile ID 387975. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871685917?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
PHILLIP MADONIA, NPI 1871685917, CMS profile ID 387975, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1871685917?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

29 matching records · $356.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 29 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–29 of 29.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.1912/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959539945 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.6611/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959684703 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.5107/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923659949 CMS
Mylan Pharmaceuticals Inc. $14.7307/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963969197 CMS
UROVANT SCIENCES INC $16.5707/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931077983 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.6906/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959972585 CMS
UROVANT SCIENCES INC $18.0306/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 931077971 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.4505/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960026793 CMS
ABBVIE INC. $2.6104/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071689 CMS
ABBVIE INC. $3.3004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071687 CMS
ABBVIE INC. $15.7204/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071685 CMS
ABBVIE INC. $21.8504/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071683 CMS
Mylan Pharmaceuticals Inc. $12.3704/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 963966079 CMS
ABBVIE INC. $3.8403/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071679 CMS
ABBVIE INC. $12.0403/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071681 CMS
PFIZER INC. $15.9503/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949076097 CMS
ABBVIE INC. $4.1103/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071677 CMS
ABBVIE INC. $7.0603/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071675 CMS
Meditrina $16.9802/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 962348611 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.0602/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959590291 CMS
Organon LLC $19.0302/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022212611 CMS
ABBVIE INC. $6.4002/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071671 CMS
ABBVIE INC. $14.4102/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071673 CMS
ABBVIE INC. $11.3101/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071669 CMS
ABBVIE INC. $11.8301/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071667 CMS
PFIZER INC. $22.5401/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949055149 CMS
ABBVIE INC. $5.0101/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071665 CMS
ABBVIE INC. $11.1701/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071663 CMS
ABBVIE INC. $8.3101/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891071661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,041.25 51
PY2020 $3,326.54 76
PY2021 $4,257.71 103
PY2022 $356.73 29
PY2023 $163.74 12
PY2024 $57.89 3
PY2025 $92.02 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $17,817.00 1
PY2023 Principal investigator $31,692.89 11
PY2022 Principal investigator $73,808.12 42
PY2021 Principal investigator $136,211.96 66
PY2020 Principal investigator $150,491.85 54
PY2019 Principal investigator $150,120.87 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $560.00 12/28/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792488455
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,291.00 12/23/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
Assess efficacyand safetyof three different doses of P2X3 antagonist in women with symptomatic endometriosis No dispute reported 06/30/2026 789126955
Principal investigator 1 Evofem Biosciences, Inc. $5,903.95 12/22/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853722783
Principal investigator 1 ABBVIE INC. $8.51 12/21/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792488001
Principal investigator 1 ABBVIE INC. $245.00 12/21/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792488029
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $22.75 12/21/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
Assess efficacyand safetyof three different doses of P2X3 antagonist in women with symptomatic endometriosis No dispute reported 06/30/2026 789129911
Principal investigator 1 Evofem Biosciences, Inc. $4,267.50 12/09/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853722759
Principal investigator 1 ABBVIE INC. $368.64 12/02/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792485265
Principal investigator 1 Evofem Biosciences, Inc. $6,678.81 12/02/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853722713
Principal investigator 1 Evofem Biosciences, Inc. $7,037.31 12/02/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853722733
Principal investigator 1 ABBVIE INC. $44.31 11/24/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792484277
Principal investigator 1 ABBVIE INC. $48.67 11/24/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792484279
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,000.00 11/23/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
BAY86-5028 Mirena extension contraception No dispute reported 06/30/2026 789147061
Principal investigator 1 ABBVIE INC. $296.70 11/17/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792483253
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $514.00 11/12/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
BAY86-5028 Mirena extension contraception No dispute reported 06/30/2026 789146017
Principal investigator 1 ABBVIE INC. $2,770.74 11/10/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792482515
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,500.00 11/01/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
A double-blind randomized placebo-controlled multicenter study to investigate efficacy and safety of elinzanetant for the treatment of vasomotor symptoms over 52 weeks in postmenopausal women No dispute reported 06/30/2026 821953289
Principal investigator 1 Evofem Biosciences, Inc. $2,665.74 10/21/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853709228
Principal investigator 1 ABBVIE INC. $1,214.64 10/14/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792479613
Principal investigator 1 ABBVIE INC. $296.70 10/14/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792479615
Principal investigator 1 ABBVIE INC. $166.40 10/07/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792478641
Principal investigator 1 Evofem Biosciences, Inc. $2,353.49 10/07/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853709201
Principal investigator 1 Evofem Biosciences, Inc. $3,492.64 09/30/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853701939
Principal investigator 1 Evofem Biosciences, Inc. $2,688.87 09/30/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853701971
Principal investigator 1 Evofem Biosciences, Inc. $6,129.47 09/22/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853701908
Principal investigator 1 Evofem Biosciences, Inc. $65.00 09/16/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853713835
Principal investigator 1 ABBVIE INC. $1,711.78 09/09/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792475173
Principal investigator 1 ABBVIE INC. $70.00 09/01/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792473761
Principal investigator 1 ABBVIE INC. $166.40 08/30/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792473265
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $20.30 08/26/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
BAY86-5028 Mirena extension contraception No dispute reported 06/30/2026 789146569
Principal investigator 1 Evofem Biosciences, Inc. $2,382.40 08/26/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853728985
Principal investigator 1 ABBVIE INC. $614.56 08/19/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792472477
Principal investigator 1 ABBVIE INC. $302.08 08/19/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792472479
Principal investigator 1 Evofem Biosciences, Inc. $1,607.54 08/12/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853728955
Principal investigator 1 Evofem Biosciences, Inc. $3,781.76 08/05/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853728925
Principal investigator 1 ABBVIE INC. $296.70 07/29/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792470557
Principal investigator 1 ABBVIE INC. $1,716.48 07/29/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792470559
Principal investigator 1 ABBVIE INC. $846.10 07/29/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792470561
Principal investigator 1 Evofem Biosciences, Inc. $3,365.42 07/28/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853703701
Principal investigator 1 Evofem Biosciences, Inc. $9,494.90 07/15/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853703659
Principal investigator 1 Travere Therapeutics, Inc. $1,000.00 07/07/2021 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES PC
021FSGS16010 No dispute reported 06/30/2026 849335259
Principal investigator 1 Travere Therapeutics, Inc. $1,000.00 07/07/2021 Non-covered Recipient Entity
NEPHROLOGY ASSOCIATES PC
021FSGS16010 No dispute reported 06/30/2026 849335261
Principal investigator 1 ABBVIE INC. $1,677.52 06/30/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792465551
Principal investigator 1 ABBVIE INC. $332.80 06/30/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792465553
Principal investigator 1 Evofem Biosciences, Inc. $2,665.74 06/23/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853723383
Principal investigator 1 ABBVIE INC. $1,427.00 06/18/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792463497
Principal investigator 1 Evofem Biosciences, Inc. $5,875.04 06/04/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853723357
Principal investigator 1 ABBVIE INC. $480.00 06/03/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792462219
Principal investigator 1 ABBVIE INC. $1,280.00 06/03/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792462221
Principal investigator 1 ABBVIE INC. $296.70 06/02/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792461765
Principal investigator 1 ABBVIE INC. $245.00 06/02/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792461767
Principal investigator 1 ABBVIE INC. $2,329.64 05/27/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792460827
Principal investigator 1 ABBVIE INC. $2,852.10 04/29/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792450439
Principal investigator 1 ABBVIE INC. $18.98 04/21/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792446483
Principal investigator 1 ABBVIE INC. $33.74 04/21/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792446489
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,000.00 04/21/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
Assess efficacyand safetyof three different doses of P2X3 antagonist in women with symptomatic endometriosis No dispute reported 06/30/2026 789125475
Principal investigator 1 ABBVIE INC. $1,894.56 03/31/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792440335
Principal investigator 1 ABBVIE INC. $499.20 03/30/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792438429
Principal investigator 1 Evofem Biosciences, Inc. $803.77 03/18/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853719189
Principal investigator 1 Evofem Biosciences, Inc. $13,166.79 03/11/2021 Non-covered Recipient Entity
MOBILE OBSTETRICS & GYNEOCOLOGY PC
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection No dispute reported 06/30/2026 853719165
Principal investigator 1 ABBVIE INC. $1,040.00 03/10/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
Phase 2, Multicenter, Double-blind (Sponsor-unblinded), Randomized, Placebo-Controlled Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome No dispute reported 06/30/2026 792432895
Principal investigator 1 ABBVIE INC. $1,510.14 03/03/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792431789
Principal investigator 1 ABBVIE INC. $804.10 03/02/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792430243
Principal investigator 1 ABBVIE INC. $890.10 01/29/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792419327
Principal investigator 1 ABBVIE INC. $1,707.78 01/28/2021 Non-covered Recipient Entity
MOBILE OBGYN PC
A Phase 3b Study to Evaluate the Long-Term Safety of Elagolix in Combination with Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792416715
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,374.00 01/11/2021 Non-covered Recipient Entity
Mobile Obstetrics And Gynecology PC Mammography
BAY86-5028 Mirena extension contraception No dispute reported 06/30/2026 789125793